Cardiovascular risk assessment: A global perspective

Nature Reviews Cardiology

Volumn 12, Issue 5, 2015, Pages 301-311

  Zhao, Dong ^a   Liu, Jing ^a   Xie, Wuxiang ^a   Qi, Yue ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; CARDIOVASCULAR DISEASES; HEALTH; PRIMARY PREVENTION;

CARDIOVASCULAR DISEASES; GLOBAL HEALTH; HUMANS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS;

EID: 84928589032     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.28     Document Type: Review

References (108)

1. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
2. Moran, A. E. et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation 129, 1483-1492 (2014).
3. Feigin, V. L. et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 383, 245-254 (2014).
4. Bonita, R. et al. Country actions to meet UN commitments on non-communicable diseases: a stepwise approach. Lancet 381, 575-584 (2013).
5. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk [online], http://www.who.int/cardiovascular-diseases/publications/Prevention-of-Cardiovascular-Disease/en/ (2007).
6. Ford, E. S. et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N. Engl. J. Med. 356, 2388-2398 (2007).
7. The World Bank. Toward a healthy and harmonious life in China: stemming the rising tide of non-communicable diseases [online], http://www.worldbank.org/content/dam/Worldbank/document/NCD-report-en.pdf (2011).
8. Pater, C. The current status of primary prevention in coronary heart disease. Curr. Control Trials Cardiovasc. Med. 2, 24-37 (2001).
9. D'Agostino, R. B. Sr, Pencina, M. J., Massaro, J. M. & Coady, S. Cardiovascular disease risk assessment: insights from Framingham. Glob. Heart 8, 11-23 (2013).
10. Huffman, M. D. et al. Quantifying options for reducing coronary heart disease mortality by 2020. Circulation 127, 2477-2484 (2013).
11. D'Agostino, R. B. Sr, Grundy, S., Sullivan, L. M. & Wilson, P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286, 180-187 (2001).
12. Kannel, W. B., McGee, D. & Gordon, T. A general cardiovascular risk profile: the Framingham Study. Am. J. Cardiol. 38, 46-51 (1976).
13. Anderson, K. M., Odell, P. M., Wilson, P. W. & Kannel, W. B. Cardiovascular disease risk profiles. Am. Heart J. 121, 293-298 (1991).
14. Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847 (1998).
15. D'Agostino, R. B., Sr. et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117, 743-753 (2008).
16. Pencina, M. J., D'Agostino, R. B. Sr, Larson, M. G., Massaro, J. M. & Vasan, R. S. Predicting the 30-year risk of cardiovascular disease: the Framingham heart study. Circulation 119, 3078-3084 (2009).
17. Goff, D. C. Jr et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 (Suppl. 2), S49-S73 (2014).
18. Conroy, R. M. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24, 987-1003 (2003).
19. Cooney, M. T., Cooney, H. C., Dudina, A. & Graham, I. M. Assessment of cardiovascular risk. Curr. Hypertens. Rep. 12, 384-393 (2010).
20. Matheny, M. et al. Systematic review of cardiovascular disease risk assessment tools. Rockville (MD): Agency for Healthcare Research and Quality (US) [online], http://www.ncbi.nlm.nih.gov/books/NBK56166/ (2011).
21. Graham, I. M. & D'Agostino, R. B. Sr. Therapeutic strategies in cardiovascular risk. Glob. Heart 8, 11-23 (2013).
22. Cooney, M. T., Dudina, A. L. & Graham, I. M. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J. Am. Coll. Cardiol. 54, 1209-1227 (2009).
23. Siontis, G. C., Tzoulaki, I., Siontis, K. C. & Ioannidis, J. P. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ 344, e3318 (2012).
24. Moons, K. G. et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 98, 683-690 (2012).
25. Diverse Populations Collaborative Group. Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function? Heart 88, 222-228 (2002).
26. Liu, J. et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 291, 2591-2599 (2004).
27. Menotti, A. et al. Comparison of multivariate predictive power of major risk factors for coronary heart diseases in different countries: results from eight nations of the Seven Countries Study, 25-year follow-up. J. Cardiovasc. Risk 3, 69-75 (1996).
28. De Backer, G. et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 10, S1-S10 (2003).
29. Marrugat, J. et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J. Epidemiol. Community Health 57, 634-638 (2003).
30. Kim, A. S. & Johnston, S. C. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 124, 314-323 (2011).
31. Truett, J., Cornfield, J. & Kannel, W. A multivariate analysis of the risk of coronary heart disease in Framingham. J. Chronic Dis. 20, 511-524 (1967).
32. Beswick, A. & Brindle, P. Risk scoring in the assessment of cardiovascular risk. Curr. Opin. Lipidol. 17, 375-386 (2006).
33. Muntner, P. et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 311, 1406-1415 (2014).
34. Wu, Y. et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation 114, 2217-2225 (2006).
35. Chow, C. K., Joshi, R., Celermajer, D. S., Patel, A. & Neal, B. C. Recalibration of a Framingham risk equation for a rural population in India. J. Epidemiol. Community Health 63, 379-385 (2009).
36. Bozorgmanesh, M., Hadaegh, F. & Azizi, F. Predictive accuracy of the 'Framingham's general CVD algorithm' in a Middle Eastern population: Tehran Lipid and Glucose Study. Int. J. Clin. Pract. 65, 264-273 (2011).
37. Goldbourt, U., Yaari, S. & Medalie, J. H. Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. A 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology 82, 100-121 (1993).
38. NIPPON DATA80 Research Group. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ. J. 70, 1249-1755 (2006).
39. Jee, S. H. et al. A coronary heart disease prediction model: the Korean Heart Study. BMJ Open 4, e005025 (2014).
40. Lee, J. et al. Risk factors and incident coronary heart disease in Chinese, Malay and Asian Indian males: the Singapore Cardiovascular Cohort Study. Int. J. Epidemiol. 30, 983-988 (2001).
41. Sritara, P. et al. Twelve-year changes in vascular risk factors and their associations with mortality in a cohort of 3499 Thais: the Electricity Generating Authority of Thailand Study. Int. J. Epidemiol. 32, 461-468 (2003).
42. Kengne, A. P. & Awah, P. K. Classical cardiovascular risk factors and all-cause mortality in rural Cameroon. QJM 102, 209-215 (2009).
43. Assmann, G., Schulte, H., Cullen, P. & Seedorf, U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur. J. Clin. Invest. 37, 925-932 (2007).
44. Panagiotakos, D. B. et al. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). Hellenic J. Cardiol. 48, 55-63 (2007).
45. Aspelund, T., Thorgeirsson, G., Sigurdsson, G. & Gudnason, V. Estimation of 10-year risk of fatal cardiovascular disease and coronary heart disease in Iceland with results comparable with those of the Systematic Coronary Risk Evaluation project. Eur. J. Cardiovasc. Prev. Rehabil. 14, 761-768 (2007).
46. Merry, A. H. et al. Risk prediction of incident coronary heart disease in The Netherlands: re-estimation and improvement of the SCORE risk function. Eur. J. Prev. Cardiol. 19, 840-848 (2012).
47. Marques-Vidal, P. et al. Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland. Eur. J. Cardiovasc. Prev. Rehabil. 15, 402-428 (2008).
48. Onat, A., Can, G., Hergenc, G., Ugur, M. & Yuksel, H. Coronary disease risk prediction algorithm warranting incorporation of C-reactive protein in Turkish adults, manifesting sex difference. Nutr. Metab. Cardiovasc. Dis. 22, 643-650 (2012).
49. Hippisley-Cox, J. et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 335, 136 (2007).
50. Hippisley-Cox, J. et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336, 1475-1482 (2008).
51. Icaza, G. et al. Estimation of coronary heart disease risk in Chilean subjects based on adapted Framingham equations [Spanish]. Rev. Med. Chil. 137, 1273-1282 (2009).
52. Ridker, P. M., Buring, J. E., Rifai, N. & Cook, N. R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297, 611-619 (2007).
53. Ridker, P. M., Paynter, N. P., Rifai, N., Gaziano, J. M. & Cook, N. R. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118, 2243-2251, (2008).
54. Mainous, A. G. 3rd et al. A coronary heart disease risk score based on patient-reported information. Am. J. Cardiol. 99, 1236-1241 (2007).
55. Lee, E. T. et al. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. Circulation 113, 2897-2905 (2006).
56. Cantin, B. et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J. Am. Coll. Cardiol. 31, 519-525 (1998).
57. Chen, L. et al. Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart. Eur. J. Cardiovasc. Prev. Rehabil. 16, 562-570 (2009).
58. Altman, D. G. & Royston, P. What do we mean by validating a prognostic model? Stat. Med. 19, 453-473 (2000).
59. Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J. & Brindle, P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 94, 34-39 (2008).
60. Ferrario, M. et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int. J. Epidemiol. 34, 413-421 (2005).
61. Cui, J. Overview of risk prediction models in cardiovascular disease research. Ann. Epidemiol. 19, 711-717 (2009).
62. Pyorala, K., De Backer, G., Graham, I., Poole-Wilson, P. & Wood, D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J. 15, 1300-1331 (1994).
63. Mann, J. I. et al. Guidelines for detection and management of dyslipidaemia. Scientific Committee of the National Heart Foundation of New Zealand. N. Z. Med. J. 106, 133-141 (1993).
64. Wood, D. et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 140, 199-270 (1998).
65. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 157, 2413-2446 (1997).
66. New Zealand Guidelines Group. New Zealand primary care handbook 2012, cardiovascular disease risk assessment, updated 2013 [online], http://www.health.govt.nz/publication/new-zealand-primary-care-handbook-2012 (2013).
67. Perk, J. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 33, 1635-1701 (2012).
68. Mosca, L. et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation 123, 1243-1262 (2011).
69. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease: a national clinical guideline [online], http://www.sign.ac.uk/guidelines/fulltext/97/ (2007).
70. James, P. A. et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507-520 (2014).
71. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J. Hypertens. 31, 1925-1938 (2013).
72. The Association of Physicians of India. Indian hypertension guidelines II [online], http://www.apiindia.org/hsi-guideline-ii.html (2011).
73. Seedat, Y. K. & Rayner, B. L. South African hypertension guideline 2011. S. Afr. Med. J. 102, 57-83 (2012).
74. National Heart Foundation of Australia. Guide to management of hypertension 2008: assessing and managing raised blood pressure in adults, updated December 2010 [online], http://www.heartfoundation.org.au/SiteCollectionDocuments/HypertensionGuidelines2008to2010Update.pdf (2010).
75. Liu, L. S. 2010 Chinese guidelines for the management of hypertension [Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 39, 579-615 (2011).
76. Ogihara, T. et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens. Res. 32, 3-107 (2009).
77. Sanchez, R. A. et al. Latin American guidelines on hypertension. Latin American Expert Group. J. Hypertens. 27, 905-922 (2009).
78. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease [online], http:// www.nice.org.uk/guidance/cg181 (2014).
79. International Atherosclerosis Society. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia [online]. http://www.athero.org/download/IASPPGuidelines-FullReport-2.pdf (2013).
80. Teramoto, T. et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 version. J. Atheroscler. Thromb. 20, 517-523 (2013).
81. Son, J., Chin, S. O. & Woo, J. Treatment guidelines for dyslipidemia: summary of the expanded second version. J. Lipid Atheroscler. 1, 45-59 (2012).
82. Reiner, Z. et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32, 1769-1818 (2011).
83. Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults [Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 35, 390-419 (2007).
84. McPherson, R., Frohlich, J., Fodor, G., Genest, J. & Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can. J. Cardiol. 22, 913-927 (2006).
85. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Position statement on lipid management 2005 [online], http://www.heartfoundation.org.au/SiteCollectionDocuments/The-lipid-position-statement.pdf (2005).
86. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
87. Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63, 2889-2934 (2014).
88. The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 144, 1045-1057 (1984).
89. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch. Intern. Med. 148, 36-69 (1988).
90. Ferket, B. S. et al. Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check? Arch. Intern. Med. 170, 27-40 (2010).
91. Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Dunn, S. P. & Urbina, E. M. Review of clinical practice guidelines for the management of LDL-related risk. J. Am. Coll. Cardiol. 64, 196-206 (2014).
92. Nakamura, H. et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368, 1155-1163 (2006).
93. Downs, J. R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622 (1998).
94. Ridker, P. M. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373, 1175-1182 (2009).
95. Mihaylova, B. et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380, 581-590 (2012).
96. Wu, Y. F. et al. Cut offs and risk stratification of dyslipidemia in Chinese adults [Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 35, 428-433 (2007).
97. Graham, I. M., Stewart, M. & Hertog, M. G. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur. J. Cardiovasc. Prev. Rehabil. 13, 839-845 (2006).
98. Pignone, M., Phillips, C. J., Elasy, T. A. & Fernandez, A. Physicians' ability to predict the risk of coronary heart disease. BMC Health Serv. Res. 3, 13 (2003).
99. Shillinglaw, B., Viera, A. J., Edwards, T., Simpson, R. & Sheridan, S. L. Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U. S. physicians. BMC Health Serv. Res. 12, 20 (2012).
100. Smith, S. C. Jr. Screening for high-risk cardiovascular disease: a challenge for the guidelines: comment on "systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check?". Arch. Intern. Med. 170, 40-42 (2010).
101. Modesti, P. A. et al. Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. J. Hypertens. 32, 951-960 (2014).
102. Allan, G. M. et al. Agreement among cardiovascular disease risk calculators. Circulation 127, 1948-1956 (2013).
103. Persell, S. D., Lloyd-Jones, D. M. & Baker, D. W. National Cholesterol Education Program risk assessment and potential for risk misclassification. Prev. Med. 43, 368-371 (2006).
104. Johnson, K. M. & Dowe, D. A. Accuracy of statin assignment using the 2013 AHA/ACC cholesterol guideline versus the 2001 NCEP ATP III guideline: correlation with atherosclerotic plaque imaging. J. Am. Coll. Cardiol. 64, 910-919 (2014).
105. Paixao, A. R., Ayers, C. R., Berry, J. D., de Lemos, J. A. & Khera, A. Atherosclerotic cardiovascular disease prevention: a comparison between the third adult treatment panel and the new 2013 treatment of blood cholesterol guidelines. Circ. Cardiovasc. Qual. Outcomes 7, 778-779 (2014).
106. Murphy, T. P., Dhangana, R., Pencina, M. J., Zafar, A. M. & D'Agostino, R. B. Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment. Atherosclerosis 216, 452-457 (2011).
107. Mendis, S. et al. Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. J. Clin. Epidemiol. 64, 1451-1462 (2011).
108. Otgontuya, D., Oum, S., Buckley, B. S. & Bonita, R. Assessment of total cardiovascular risk using WHO/ISH risk prediction charts in three low and middle income countries in Asia. BMC Public Health 13, 539 (2013).